Does female hormone therapy increase the risk of retinal vascular occlusion?


  • Heather Mason
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Researchers conducted a cohort study to determine whether female hormone therapy (FHT) was associated with an increased risk of retinal artery occlusion (RAO) or retinal vein occlusion (RVO).

The analysis included a total of 205,304 women who filled a prescription for FHT and 755,462 matched control individuals. The primary outcome was the incidence of a new diagnosis of RAO or RVO. Cox proportional hazard regression modelling with inverse probability of treatment weight was used to assess the hazard ratio (HR) for a new diagnosis of RAO or RVO relative to filling a prescription for FHT.

Results reported in JAMA Opthalmology reveal 41 cases of RAO and 68 cases of RVO in the FHT cohort. In comparison, there were 373 cases of RAO and 617 cases of RVO in the control cohort. The Cox regression analysis showed no difference in hazard for RAO, RVO, or combined outcomes in the FHT cohort relative to the control cohort.

These findings suggest that filling a prescription for FHT does not increase the risk of RAO or RVO, and that the incidence of these two situations is very low.